Bayer Aktiengesellschaft (BAYRY)
| Previous close | 7.04 |
| Open | 6.99 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.96 - 7.08 |
| 52-week range | 6.96 - 16.81 |
| Volume | |
| Avg. volume | 2,041,530 |
| Market cap | 27.822B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.79 |
| Earnings date | N/A |
| Forward dividend & yield | 0.03 (0.42%) |
| Ex-dividend date | 29 Apr 2024 |
| 1y target est | 28.89 |
FortunePharmaceutical giant Bayer is getting rid of bosses and asking nearly 100,000 workers to ‘self-organize’ to save $2.15 billion
Chief executive Bill Anderson says he doesn’t want it to be a "lame" company, but its stock has still tanked 50%.
Insider MonkeyHere’s Why Bayer Aktiengesellschaft (BAYRY) Detracted in Q1
Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. For the quarter ended March 31, 2024, the fund returned 0.11% compared to the MSCI World ex U.S. Index benchmark’s 5.59% return. Since its inception in September 1992, the fund returned an […]
- Reuters
Judge slashes Bayer $1.56 billion Roundup verdict to $611 million
A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Friday it is appealing. The German company's Monsanto unit had been found liable in November by a Cole County, Missouri, jury to Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California, who blamed their non-Hodgkin's lymphoma on their exposure to Roundup.
